Akero Therapeutics (AKRO) Stock Forecast, Price Target & Predictions
AKRO Stock Forecast
Akero Therapeutics stock forecast is as follows: an average price target of $46.00 (represents a 43.53% upside from AKRO’s last price of $32.05) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
AKRO Price Target
AKRO Analyst Ratings
Akero Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 17, 2024 | Ed Arce | H.C. Wainwright | $50.00 | $26.97 | 85.39% | 56.01% |
Jun 12, 2024 | Edward Nash | Canaccord Genuity | $56.00 | $23.43 | 139.01% | 74.73% |
Jun 10, 2024 | Andy Chen | Wolfe Research | $40.00 | $22.99 | 73.99% | 24.80% |
May 15, 2024 | Liisa Bayko | Evercore ISI | $38.00 | $20.30 | 87.19% | 18.56% |
Oct 11, 2023 | Ed Arce | H.C. Wainwright | $40.00 | $15.04 | 165.96% | 24.80% |
Sep 13, 2022 | Liisa Bayko | Evercore ISI | $50.00 | $29.05 | 72.12% | 56.01% |
Akero Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 4 |
Avg Price Target | - | $50.00 | $46.00 |
Last Closing Price | $32.05 | $32.05 | $32.05 |
Upside/Downside | -100.00% | 56.01% | 43.53% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jun 12, 2024 | Canaccord Genuity | Buy | Buy | Hold |
Jun 10, 2024 | Wolfe Research | - | Outperform | Initialise |
May 15, 2024 | Evercore ISI | Outperform | Outperform | Hold |
Sep 14, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
Akero Therapeutics Financial Forecast
Akero Therapeutics Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Akero Therapeutics EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Akero Therapeutics Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-72.62M | $-72.39M | $-69.85M | $-68.47M | $-68.47M | $-60.75M | $-57.38M |
High Forecast | $-72.62M | $-72.39M | $-69.85M | $-68.47M | $-68.47M | $-56.70M | $-57.38M |
Low Forecast | $-72.62M | $-72.39M | $-69.85M | $-68.47M | $-68.47M | $-68.17M | $-57.38M |
Surprise % | - | - | - | - | - | - | - |
Akero Therapeutics SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Akero Therapeutics EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-1.05 | $-1.05 | $-1.01 | $-0.99 | $-0.99 | $-0.88 | $-0.83 |
High Forecast | $-1.05 | $-1.05 | $-1.01 | $-0.99 | $-0.99 | $-0.82 | $-0.83 |
Low Forecast | $-1.05 | $-1.05 | $-1.01 | $-0.99 | $-0.99 | $-0.99 | $-0.83 |
Surprise % | - | - | - | - | - | - | - |
Akero Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
PASG | Passage Bio | $0.60 | $6.00 | 900.00% | Buy |
BDTX | Black Diamond Therapeutics | $2.99 | $14.75 | 393.31% | Buy |
INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
VKTX | Viking Therapeutics | $63.14 | $100.50 | 59.17% | Buy |
AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
RNA | Avidity Biosciences | $44.82 | $54.50 | 21.60% | Buy |
PTGX | Protagonist Therapeutics | $46.76 | $50.00 | 6.93% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
AKRO Forecast FAQ
Is Akero Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Akero Therapeutics (AKRO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of AKRO's total ratings.
What is AKRO's price target?
Akero Therapeutics (AKRO) average price target is $46 with a range of $38 to $56, implying a 43.53% from its last price of $32.05. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Akero Therapeutics stock go up soon?
According to Wall Street analysts' prediction for AKRO stock, the company can go up by 43.53% (from the last price of $32.05 to the average price target of $46), up by 74.73% based on the highest stock price target, and up by 18.56% based on the lowest stock price target.
Can Akero Therapeutics stock reach $50?
AKRO's highest twelve months analyst stock price target of $56 supports the claim that Akero Therapeutics can reach $50 in the near future.
What are Akero Therapeutics's analysts' financial forecasts?
Akero Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-187M (high $-183M, low $-194M), average SG&A $0 (high $0, low $0), and average EPS is $-2.698 (high $-2.639, low $-2.805). AKRO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-283M (high $-283M, low $-283M), average SG&A $0 (high $0, low $0), and average EPS is $-4.097 (high $-4.097, low $-4.097).